Although the landscape of heart failure continues to rapidly evolve, and the widespread use of evidence-based pharmaceutical and device therapies has improved overall survival rates, mortality rates in heart failure patients remain high. Understanding the mode of death in heart failure is particularly important if we are to improve survival. This study reviews the evaluation of modes of death from heart failure and discusses the therapies, both pharmaceutical and device, that are useful in preventing these sequelae.
American Heart Association.Heart Disease and Stroke Statistics—2006 Update. Dallas, TX: American Heart Association; 2006.
2.
Mosterd A., Cost B., Hoes AW, et al. The prognosis of heart failure in the general population: the Rotterdam Study. Eur Heart J.2001;22:1318-1327.
3.
Levy D., Kenchaiah S., Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med.2002;347:1397-1402.
4.
Parkash R., Stevenson WG, Epstein LM, Maisel WHPredicting early mortality after implantable defibrillator implantation: a clinical risk score for optimal patient selection. Am Heart J.2006;151:397-403.
5.
Sanders GD, Hlatky MA, Owens DKCost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med.2005;353:1471-1480.
6.
Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). American College of Cardiology Website. http://www.acc.org/qualityandscience/clinical/guidelines/failure/update/index.pdf; 2005.
7.
Cioffi G., Tarantini L., De Feo S., et al. Pharmacological left ventricular reverse remodeling in elderly patients receiving optimal therapy for chronic heart failure. Eur J Heart Fail. 2005;7:1040-1048.
8.
Ho Kkl, Anderson KM, Kannel WB, Grossman W., Levy D.Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 1993; 88:107-115.
9.
Kannel WB, Plehn JF, Cupples LACardiac failure and sudden death in the Framingham Study. Am Heart J.1988;115:869-875.
10.
Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. JAMA.2004;292:344-350.
11.
SOLVD Investigators.Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med.1991;325:293-302.
12.
CIBIS-II Investigators and Committees.The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial . Lancet. 1999;353:9-13.
13.
MERIT-HF Investigators.Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-2007.
14.
Poole-Wilson PA, Swedberg K., Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362:7-13.
15.
Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med.2005 ;352:225-237.
16.
Bradley DJ, Bradley EA, Baughman KL, et al. Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. JAMA.2003;289:730-740.
17.
Kadish A., Dyer A., Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med.2004 ;350:2151-2158.
18.
Connolly SJ , Hallstrom AP, Cappato R., et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest StudyHamburg. Canadian Implantable Defibrillator Study. Eur Heart J.2000; 21: 2071-2078.
19.
Senni M., Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation. 1998;98:2282-2289.
20.
Senni M., Redfield MMHeart failure with preserved systolic function. A different natural history?J Am Coll Cardiol.2001;38:1277-1282.
21.
Narang R., Cleland JG, Erhardt L., et al. Mode of death in chronic heart failure. A request and proposition for more accurate classification. Eur Heart J.1996;17: 1390-1403.
22.
Goldman S., Johnson G., Cohn JN, Cintron G., Smith R., Francis G.Mechanism of death in heart failure. The Vasodilator-Heart Failure Trials. The V-HeFT VA Cooperative Studies Group. Circulation. 1993;87(suppl): V124-V131.
23.
Cohn JN, Archibald DG, Ziesche S., et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med.1986;314:1547-1552.
24.
CONSENSUS Trial Study Group.Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med.1987;316:1429-1435.
25.
Cohn JN, Johnson G., Ziesche S., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med.1991;325:303-310.
26.
Packer M., Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med.1996;334:1349-1355.
27.
Digitalis Investigation Group.The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med.1997; 336:525-533.
28.
Curtis JP, Sokol SI, Wang Y., et al. The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure. J Am Coll Cardiol.2003;42:736-742.
29.
Pitt B., Zannad F., Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators . N Engl J Med.1999;341:709-717.
30.
Poole-Wilson PA, Uretsky BF, Thygesen K., Cleland JG, Massie BM, Ryden L.Mode of death in heart failure: findings from the ATLAS trial. Heart. 2003;89:42-48.
31.
Packer M., Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure . N Engl J Med.2001;344:1651-1658.
32.
Cleland JG, Daubert JC, Erdmann E., et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med.2005;352:1539-1549.
33.
Josephson M. , Wellens HJImplantable defibrillators and sudden cardiac death. Circulation. 2004; 109:2685-2691.
34.
Myerburg RJ , Kessler KM, Castellanos A.Sudden cardiac death. Structure, function, and time-dependence of risk. Circulation. 1992;85(suppl):12-110.
35.
AVID Investigators.A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med.1997;337:1576-1583.
36.
Kuck KH, Cappato R., Siebels J., Ruppel R.Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102:748-754.
37.
Bristow MR, Saxon LA, Boehmer J., et al. Cardiacresynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med.2004;350:2140-2150.
38.
The Cardiac Arrhythmia Suppression Trial (CAST) Investigators.Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med.1989;321:406-412.
39.
Massie BM, Fisher SG, Radford M., et al. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. CHF-STAT Investigators . Circulation. 1996;93:2128-2134.
40.
Packer M., Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure . N Engl J Med.2001;344:1651-1658.
41.
Beta-Blocker Evaluation of Survival Trial Investigators.A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med.2001; 344:1659-1667.
42.
Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J.2005;26:215-225.
43.
Torp-Pedersen C., Poole-Wilson PA, Swedberg K., et al; the COMET Investigators.Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure—COMET . Am Heart J.2005;149:370-376.
44.
Moss AJ, Zareba W., Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med.2002;346: 877-883.
45.
Davies MJ, Thomas A.Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death . N Engl J Med.1984;310:1137-1140.
46.
Uretsky BF, Thygesen K., Armstrong PW, et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation. 2000 ; 102:611-616.
47.
Reiffel JADrug and drug-device therapy in heart failure patients in the post-COMET and SCD-HeFT era. J Cardiovasc Pharmacol Ther.2005;10(suppl):S45-S58.
48.
Pratt CM, Greenway PS, Schoenfeld MH, Hibben ML, Reiffel JAExploration of the precision of classifying sudden cardiac death. Implications for the interpretation of clinical trials. Circulation. 1996;93:519-524.
49.
Kjekshus J.Arrhythmias and mortality in congestive heart failure. Am J Cardiol.1990;65:421-481.
50.
Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA.2003;289:2685-2694.
51.
Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med.2001;345:1435-1443.
52.
Packer M., Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study. Circulation. 2002;106:2194-2199.
53.
Greenberg H. , Case RB, Moss AJ, Brown MW, Carroll ER, Andrews MLAnalysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II). J Am Coll Cardiol.2004;43:1459-1465.
54.
Carson P., Anand I., O'Connor C., et al. Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. J Am Coll Cardiol.2005;46:2329-2334.
